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a  b  s  t  r  a  c  t
The  success  of Gavi,  the  Vaccine  Alliance  depends  on  the  vaccine  markets  providing  appropriate,  afford-
able  vaccines  at  sufﬁcient  and  reliable  quantities.  Gavi’s  current  supplier  base  for new  and  underutilized
vaccines,  such  as  the human  papillomavirus  (HPV),  rotavirus,  and  the  pneumococcal  conjugate  vaccine  is
very  small.  There  is growing  concern  that  following  globalization  of laws  on  intellectual  property  rights
(IPRs)  through  trade  agreements,  IPRs  are  impeding  new  manufacturers  from  entering  the  market  with
competing vaccines.  This article  examines  the  extent  to which  IPRs,  speciﬁcally  patents,  can  create  such
obstacles,  in particular  for  developing  country  vaccine  manufacturers  (DCVMs).  Through  building  patent
landscapes  in  Brazil,  China,  and  India and  interviews  with  manufacturers  and  experts  in the  ﬁeld,  we
found  intense  patenting  activity  for the  HPV  and  pneumococcal  vaccines  that could  potentially  delay  theuman papillomavirus vaccines
otavirus vaccines
neumococcal conjugate vaccines
rade
atents
accine manufacturers
eveloping country manufacturers
entry  of new  manufacturers.  Increased  transparency  around  patenting  of vaccine  technologies,  stricter
patentability  criteria  suited  for local  development  needs  and  strengthening  of IPRs  management  capabil-
ities  where  relevant,  may  help  reduce  impediments  to  market  entry  for new  manufacturers  and  ensure
a  competitive  supplier  base  for quality  vaccines  at  sustainably  low  prices.
© 2015  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).. Introduction
Established in 2000, Gavi is a public private partnership that
acilitates access to lifesaving vaccines for low-income countries,
sing an innovative model to pool donor funds and support country
mmunization priorities. From inception to December 2013, Gavi
ad invested US$8.7 billion in over 70 countries, helping to pre-
ent over six million future deaths through immunization. Gavi’s
uccess depends on the vaccine markets providing appropriate,
ffordable vaccines at sufﬁcient and reliable quantities. “Shap-
ng vaccine markets” is therefore, one of four strategic goals in
he Gavi Alliance strategy 2011–2015 [1]. The aim is to ensure
∗ Corresponding author. Tel.: +41 229096500.
E-mail address: ANguyen@gavi.org (A. Nguyen).
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264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article 
/).an adequate supply of quality vaccines that meet demand at
low and sustainable prices. Through targeted interventions and
strategic procurement, Gavi tries to encourage new vaccine man-
ufacturers to enter the market as a means to increase competition,
thereby increasing supply and putting a downward pressure on
prices [2].
The current supplier base for many of the new vaccines pur-
chased by Gavi is very small, but progress has been made in
some product markets: in 2001, Gavi began to procure pentavalent
vaccines—which combine the antigens for ﬁve infectious diseases
in a single shot—from just one manufacturer [3]. By 2014, this has
increased to six manufacturers, two  of which are based in India.
While historically, manufacturers based in the United States and
Europe have dominated most vaccine markets, development and
manufacturing capacity has increased in other parts of the world
over the last two  decades [2]. Nevertheless, no developing coun-
try manufacturers have yet brought follow-on versions of newer
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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accines, such as the human papillomavirus (HPV), rotavirus, and
neumococcal conjugate vaccines to market [3–5].
Simultaneously, international trade agreements require
ountries with vaccine manufacturing capabilities to provide
atent protection for pharmaceutical and biological products
nder the WTO  agreement on trade-related aspects of intellectual
roperty (TRIPS). This article summarizes the results of a study
unded by Gavi, which explored whether patents and other
ntellectual property rights (IPRs) act as barriers to new manufac-
urers and especially developing country vaccine manufacturers
DCVMs), particularly for the HPV, rotavirus, and pneumococcal
onjugate vaccines. The objectives of the study were to (1) identify
ocumented and potential effects, if any, of IPRs (in particular
atents) on access to essential vaccine technologies that enable
anufacturers to develop new vaccines; (2) identify perceived
arriers that may  deter or delay market entry of manufacturers.
. Methods
The study used three approaches: (1) literature surveys to
dentify potential barriers that IPRs may  create for research,
evelopment, and commercialization of novel vaccines and/or
ombinations of existing vaccines by competitive suppliers. This
ncluded a review of peer-reviewed papers, and policy docu-
ents relevant to vaccine development and intellectual property.
esearchers evaluated existing mechanisms to promote vac-
ine development and purchasing of vaccines for Gavi eligible
ountries through the reduction of IPRs barriers, including the
RIPS ﬂexibilities (See Supplementary Data for details of literature
eview).
(2) Case studies to assess and analyze the impact of IPRs on
he development of HPV, rotavirus, and pneumococcal conjugate
accines. These vaccines were chosen because they are relatively
ew and have been prioritized for Gavi funding. They also have
een cited as having complex IP landscapes [6]. The research
ncluded unstructured interviews with expert informants, such as
esearchers, technology transfer professionals, representatives of
ublic health agencies, and developing country vaccine manufac-
urers (See Supplementary Data for details of methods used for
nterview study and qualitative analysis). To build a patent land-
cape, a search was made for US patents or international patent
pplications (PCT) using keywords in the description and claims of
atent documents. Given the various technologies that go into man-
facturing a vaccine, the keywords used were deliberately broad
n order to capture as many relevant patents as possible. Inventor
nd names were also used to build upon key word searches. Addi-
ional searches used names of companies currently marketing these
accines as “assignee/applicant”. Patent searches were focused on
hree countries, India, Brazil and China, with established vaccine
anufacturing capacity from which Gavi already procures or plans
o procure vaccines and in which manufacturers are known to work
n the development of one or more of the three vaccines reviewed
n the case studies. Patent data are current as of June 30 2012 (See
upplementary Data for details of methods used for building patent
andscapes). WIPO recently released a report with patent land-
capes of vaccines, which included the pneumococcal vaccines but
ot HPV and rotavirus vaccines [7]. The WIPO analysis was  con-
ucted at the same time as our study and while we  identiﬁed a
imilar number of Patent Cooperation Treaty (PCT) applications as
he WIPO report, some differences were observed between the PCV
andscapes as a result of different searching strategies.(3) An analysis of the landscape of stakeholders and policy
roposals for reducing IPR barriers to facilitate development of
ew and underutilized vaccines. This included literature reviews
nd interviews with expert informants representing importantine 33 (2015) 6366–6370 6367
stakeholder groups to solicit views on needs related to IPR man-
agement and potential solutions.
3. Results
3.1. Human papillomavirus vaccine
We identiﬁed 93 patents ﬁled in the US or as PCT applications
that would be relevant to the manufacturing of HPV vaccines. Of
these the largest number of applications (43) has been ﬁled in
China. China also has the highest number of granted patents (16).
Brazil has only granted one patent to date out of 31 ﬁled. India has
granted 13 out of the 30 applications ﬁled (Fig. 1). Not surprisingly,
the two companies with licensed HPV vaccines, GlaxoSmithKline
(GSK) and Merck, dominate the patenting activity for HPV vaccine
technologies in Brazil, China, and India (Supplementary Table 1–3).
Although the patent landscape for HPV vaccines is quite com-
plex, the analysis suggests patents should not completely block
new manufacturers from producing biosimilar vaccines based on
major virus capsid protein L1 virus like particles (VLPs) equiva-
lent to Cervarix and Gardasil or second-generation vaccines based
on L2 capsid protein VLPs. However, given the number of patents
identiﬁed and the subjective nature of claims interpretation, new
manufacturers and in particular DCVMs do face uncertainty in navi-
gating these patents, which could increase transaction costs and/or
delay end products coming to market. Working around some key
patents may  also add costs and time to the development process.
For example, representatives of one Indian manufacturer stated
that while their in-house preliminary FTO analysis suggested there
was freedom to operate for developing an LI VLP-based bivalent or
quadrivalent vaccine in India, patents ﬁled by GSK separately claim
a “Two dose regimen” for compositions containing HPV 16 and 18
VLPs and “providing cross-protection against other oncogenic HPV
strains” such as HPV 31, 33, 45, 52, and 58 [8]. The manufacturer
indicated that the scope of these patent claims is unclear and the
patent status, particularly in other developing countries, are not
fully known. Protection against HPV 33, 45, 52, and 58 is especially
relevant to vaccines made for developing countries as epidemio-
logical studies show these strains are highly prevalent in parts of
Asia and Africa [9].
3.2. Rotavirus vaccine
We identiﬁed 29 patents ﬁled in the US or as PCT applications
that may  be relevant to the manufacturing of rotavirus vaccines.
GSK, the manufacturer of the vaccine Rotarix, has the most number
of patents ﬁled across the three countries. Merck, the manufacturer
of Rotateq, does not appear to have any patents granted in Brazil,
China, or India (Supplementary Table 1–3). Our landscape includes
patents on technology underlying the bovine reassortant rotavirus
vaccine (BRV) owned by the United States National Institutes of
Health (NIH). This patent has been refused in Brazil, but is under
appeal, and has been granted in China and India where it has been
licensed to a number of developing country vaccine manufactures
(DCVMs). SII and Bharat Biotech have ﬁled applications for their
vaccine candidates as well.
Based on analysis of the patent landscape, there do not appear
to be any patent related barriers in Brazil, China, or India that
would prevent the production of a BRV. However, new manufac-
turers seeking to make follow on versions of GSK’s Rotarix vaccine
may  have to work around some of these patents depending on
which markets they plan to sell their vaccines in. Representatives
of WHO  [10] also highlighted that patents on a liquid formulation
for a rotavirus vaccine could be an impediment. Merck has broad
patent claims on a liquid formulation of BRV, which have been
6368 S. Chandrasekharan et al. / Vaccine 33 (2015) 6366–6370
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led in many developing countries [11]. Although this study did
ot ﬁnd any patent on a liquid formulation awarded to Merck in
razil, China, or India, it remains possible that Merck has received
rotection for this technology in other developing countries and
he patent may  be important depending on the markets in which
anufacturers plan to sell their vaccines.
.3. Pneumococcal conjugate vaccine
This vaccine has by far the most patenting activity of the three
accines. Our study identiﬁed 106 PCT applications potentially rel-
vant to the manufacturing of pneumococcal vaccines. GSK, the
anufacturer of Synﬂorix, has ﬁled the most number of patents.
SK has received several patents in China and India, but none as
et in Brazil. Pﬁzer (previously Wyeth), the manufacturer of Pre-
nar, has the second most number of patents ﬁled across the three
ountries (Supplementary Table 1–3).
The patent landscape around pneumococcal vaccines in Brazil,
hina, and India is complex with GSK in particular owning a large
umber of patents. Panacea Biotech has challenged one of GSK’s
atent applications in India [12]. Based on the analysis of the patent
andscape and from experiences of stakeholders, it is clear that
CVMs face signiﬁcant patent related impediments for producing
lternative pneumococcal conjugate vaccines. While some man-
facturers like Panacea have taken a more aggressive approach
y challenging key patents, others appear mainly to be working
round them. A number of DCVMs are engaged in product develop-
ent partnerships for pneumococcal vaccines. The pneumococcal
accine project at PATH supported by the Bill & Melinda Gates Foun-
ation supports SII and the collaboration between the Chengdu
nstitute (China) and the Biovac Institute (South Africa) [13,14]. SII
s developing two different pneumococcal conjugate vaccine and
ccording to a representative of PATH, SII conducted a detailed
TO analysis and also worked around several patents. One of the
mportant steps in enabling SII’s vaccine development was  licens-
ng technology for expression of recombinant protein that will be
sed as a carrier protein for their polysaccharide conjugate vaccine
rom Pfenex [15]. SII identiﬁed this technology early in the devel-
pment process because they were trying to reduce their risk of
nfringing patents.PATH is working with Butantan on developing a whole cell
nactivated pneumococcal vaccine and conﬁrmed that there are no
P barriers for developing this vaccine. As representatives of PATH
ndicated, owning or co-owning the patent is one IP managementjugate and Rotavirus Vaccines in Brazil, China and India.
strategy that PATH uses for increasing access to vaccine technolo-
gies for DCVMs [16].
Additionally, Butantan is developing a pneumococcal conju-
gate vaccine focusing on serotypes most prevalent in Brazil. Patent
issues were encountered and Butantan had to develop their own
conjugation methods. IP issues were also encountered for one of
the proteins, pneumolysin, which Butantan had planned to use in
this vaccine. The process of working around these patents added
time to their process but did not appear to signiﬁcantly delay the
product development [17].
A vaccine manufacturer from India stated that in their com-
bined FTO analysis, several patents ﬁled by GSK and Pﬁzer in India
and other developing countries were ﬂagged as potential imped-
iments. The manufacturer, however, found ways to work around
these patents and developed several new technologies during their
R&D process, in part to avoid infringing patents. Representatives
indicated that patents on conjugation methods were perhaps the
most challenging to work around in terms of both time and effort
required [8].
4. Discussion
Findings from this study demonstrate that DCVMs remain con-
cerned about uncertainties surrounding patent claims and face
difﬁculties in assessing the complex IP space of the human papil-
lomavirus (HPV), rotavirus, and pneumococcal conjugate vaccines.
The concerns are most pronounced for pneumococcal conjugate
vaccines, the area with the most patenting activity. As such, patents
can present obstacles to new manufacturers from developing
countries that wish to enter the market in any step of the develop-
ment process starting from preclinical R&D, to scale up, formulation
and licensure in the markets of choice, and hence may  alter their
decision pathways of independent development or seeking access
to IPRs through licensing at each step [18].
However, the extent to which patent barriers are rated limiting
or surmountable, likely varies for each vaccine. Some manufac-
turers expressed that patents created uncertainty and navigating
them increased transaction costs and added to their development
timelines. Other experts believe that the challenges patents present
could be worked around or removed through the right legal frame-
works due to their lack of inventiveness.
These differing views beg the question, what constitutes a bar-
rier? Is it only when a patent cannot be worked around? Or are
patents a barrier when they add uncertainty or delay competition?
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Greater attention to these issues through technical support in IP
management and FTO analyses, monitoring developments in theS. Chandrasekharan et al. 
hese questions need to be explored further as the current nar-
atives do not address this nuance. Our ﬁndings suggest that in
he case of some vaccines (HPV and pneumococcal) patents create
mpediments. More worryingly, following the continued liberal-
zation of IPRs and trade laws, patents could increasingly become a
arrier for new vaccine development. This is reﬂected in the pneu-
ococcal and HPV patent landscapes and the increasing number of
atents being ﬁled by multinational companies.
The authors of the study therefore identiﬁed the following steps
o better understand and reduce IP barriers (real or perceived) in
rder to improve competition in the vaccines marketplace. It must
e underlined that these recommendations represent the views of
he authors and does not commit Gavi or any of its partners.
.1. (i) Encourage efforts to improve patent transparency
The study found a need for improved transparency around
atenting of vaccine related technologies. At present there is no
echanism or provision available online to access information per-
aining to “Complete list of countries a particular patent application
as been ﬁled”. Obtaining such information remains a concern in
aking decisions about freedom to operate in potential markets.
ne potential solution is to establish a partnership with WIPO
nder its “Development Agenda Project on Developing Tools for
ccess to Patent Information” and support the development of a
ublic database for the three vaccines studied here [19]. While
uch information may  not amount to the standard required to make
reedom to operate (FTO) decisions it could help reduce the time
nd resources spent on such issues (the patent landscapes created
hrough the study will be made publicly available by the authors).
.2. (ii) Encourage IPR management capacity building efforts for
CVMs
This study identiﬁed that DCVMs have highly variable resources
nd capacities for IP management. Particular areas of need raised
y DCVMs include information about licensing negotiations to
mprove technology transfer. Supporting and augmenting these
apacities through training and development of resources like a
asebook on best practices for IPRs management speciﬁcally for
accine technologies is recommended. Technical support could
lso include engaging legal experts in governments, nonproﬁt, and
ndustrial sectors (e.g., pharmaceutical companies) outside of gov-
rnments who may  be willing to provide services (pro bono, at low
ost or paid for by third parties) for important activities like legal
nterpretation and risk assessment. Engaging with vaccine research
nd development funders, universities and nonproﬁt institutions
n IPR management issues may  further help the development of
esources and identify opportunities for policy development.
.3. (iii) Encourage technical support to developing countries in
he use of TRIPS ﬂexibilities and in the design of IP laws
Since the current environment of free trade agreements may
urther heighten IP barriers, patents may  play a bigger role in the
uture in inﬂuencing manufacturers’ decisions to develop innova-
ive vaccines in a timely manner. As more patents are ﬁled they may
ecome an obstacle (whether granted or not) simply by creating a
evel of uncertainty that is not a feasible risk to some manufac-
urers. Increased ﬁling of patent applications with broad claims or
hich are not merited because they are not new or lack inventive-
ess could also deter companies or governments from supporting
nnovative vaccine development. The latter may  have other nega-
ive consequences, such as creating mistrust among governments
n developing countries on collaborative vaccine development
rojects [20]. It is important for the vaccine community to provideine 33 (2015) 6366–6370 6369
technical support to developing country governments in the cre-
ation of IP laws that not only support innovation and respect
international law but also safeguard public health access against
unmerited patents. Indeed, as has been demonstrated in other dis-
ease areas where patents have posed problems to access, creating
patent laws with stricter patentability criteria that weed out low
quality patents can help remove some of the barriers. Although
we do not go into discussion about the merits of the patents cov-
ered in this study, our preliminary review of some of the patents
and their prosecution histories show them to be lacking merit with
claims not meeting patentability criteria. Stricter legal standards
for patentability that TRIPS ﬂexibilities permit can remedy such
patents becoming barriers.
4.4. (iv) Continue to monitor and further explore how IPR issues
are affecting vaccine development
There is a dearth of empirical data on whether and exactly how
IP and in particular patents, affect vaccine R&D projects. While
studies like this one provide a “snapshot,” continuous engagement
with appropriate stakeholders will generate greater insight. Fur-
ther empirical studies may  be needed on IP issues with respect
to emerging vaccines to anticipate any potential barriers. Further-
more, given trends of increased patenting of vaccine technologies
and the evolving landscape of vaccine manufacturing itself, such
stakeholder engagement and IP monitoring will allow for policy-
making that is grounded in real-world experiences.
There are some limitations that must be considered while inter-
preting the ﬁndings from this study. First, the study focused on
DCVMs in India, China, and Brazil and cannot be generalized to all
DCVMs or vaccine manufacturers. Second, some manufacturers did
not respond to interview requests and we cannot generalize our
ﬁndings to all DCVMs even within a country. Furthermore, those
interviewed may  not have fully disclosed details of their IPRs man-
agement strategies in order to protect their competitive advantage
or conﬁdentiality agreements. Third, the study did not extensively
sample public funders of vaccine research or NGOs involved in vac-
cine development. Finally, as with all methodologies for patent
searching there are a number of limitations for this landscape.
Given the various technologies that contribute to each vaccine, even
broad search terms may  not capture patents for some technologies,
patent databases may  not always be up to date and information
obtained may  have errors. In view of these limitations, the patent
landscapes in the study should not be taken as legal advice or as
a freedom to operate (FTO) opinion. Nevertheless, they may con-
stitute a useful starting point to conduct more in-depth analysis
and the patent landscapes may  serve as a base for more detailed
analysis of patenting behavior.
5. Conclusion
This study found that IPRs, particularly patents or perceptions
thereof, can create obstacles for developing country vaccine man-
ufacturers to enter into the vaccine market. Based on our ﬁndings,
we suggest that improved transparency around patenting of vac-
cine technologies, stricter patentability criteria suited to local needs
and strengthening of IPRs management capabilities where relevant,
may  be necessary in order to reduce patent related impediments.industry and sustained engagement with stakeholders for system-
atic need assessment and identifying solutions can help encourage
a competitive supplier base for quality vaccines at sustainably low
prices.
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ppendix A. Supplementary data
Supplementary data associated with this article can be found, in
he online version, at http://dx.doi.org/10.1016/j.vaccine.2015.08.
63.
eferences
[1] GAVI Alliance. GAVI Alliance Strategy 2011–2015 and 2013 Progress report.
Available at http://www.gavialliance.org.
[2] GAVI Alliance. Available at: www.gavialliance.org.
[3] GAVI Alliance. GAVI Alliance Progress Report 2006; 2006. Available at:
http://www.gavialliance.org/library/publications/gavi-progress-reports/gavi-
alliance-progress-report-2006.
[4] Pagliusi S, Leite LC, Datla M, Makhoana M,  Gao Y, Suhardono M,  et al. Developing
Countries Vaccine Manufacturers Network: doing good by making high-quality
vaccines affordable for all. Vaccine 2013;31(April (Suppl. 2)):B176–83. http://
www.ncbi.nlm.nih.gov/pubmed/23598479.
[5]  WHO. Increasing access to vaccines through technology transfer and local pro-
duction. World Health Organization; 2011.
[6] GAVI Alliance. The GAVI Alliance Strategy 2011–2015 and Business Plan.
GAVI Alliance. Available at: http://www.gavialliance.org/library/publications/
pledging-conference-for-immunisation/4–gavi-strategy-business-plan/.
[7] WIPO. Patent Landscape Report Project, Vaccines for Selected Infectious
Diseases; 2012. Available at: http://www.wipo.int/patentscope/en/programs/
patent landscapes/reports/vaccines.html.
[8]  Representatives of Indian Vaccine Manufacturer, India; 2012, April 13. Personal
communication.
[9] Clifford GM,  Gallus S, Herrero R, Munos N, Snijders PJF, Vaccarella S,
et  al. Worldwide distribution of human papillomavirus types in cytologically
[
[ine 33 (2015) 6366–6370
normal women  in the International Agency for Research on Cancer HPV
prevalence surveys: a pooled analysis. Lancet 2005;366(September (9490)):
991–8.
10] Martin Friede. Innovation, information evidence and research. Switzerland:
WHO; 2012, March 22. Personal communication.
11] Krattiger A, Mahoney RT, Nelsen L. rotavirus Vaccine: NIH Ofﬁce of Technology
Transfer. CaseStudy13. In: Krattiger A, et al., editors. Executive guide to intellec-
tual property management in health and agricultural innovation: a handbook
of best practices. MIHR (Oxford, UK), PIPRA (Davis, USA), Oswaldo Cruz Foun-
dation (Fiocruz, Rio de Janeiro, Brazil), and bioDevelopments- International
Institute (Ithaca, USA); 2007.
12] Panacea Biotech v Glaxo Biologicals, Indian Patent Application No.
4849/KOLNP/2007.
13] Milstien JB, Kaddar M.  The role of emerging manufacturers in access to inno-
vative vaccines of public health importance. Vaccine 2010;28(9):2115–21.
14] Increasing access to vaccines through technology transfer and local production.
WHO; 2011. Available at: http://www.who.int/phi/publications/Increasing
Access to Vaccines Through Technology Transfer.pdf.
15] Pfenex Inc. Through its reagent proteins business division announces submis-
sion  of biologics master ﬁle for recombinant CRM197 to US FDA; 2011, May  7.
Available at: http://www.pfenex.com/news/details/18.
16] Personal communication Mark Alderson, PATH, USA, April 19, 2012.
17] Personal communication Luciana Leite, Instituto Butantan, Brazil, April 5, 2012.
18] Wilson P. Giving developing countries the best shot: An overview of vaccine
access and R&D, 2010, Oxfam International. Padmanabhan, S., et al., Intellectual
property, technology transfer and manufacture of low-cost HPV vaccines in
India. Nat Biotechnol 2010;27:671–8.19] Personal Communication Vaccine manufacturer, India, March 20, 2012.
20] Fidler DP. Negotiating equitable access to inﬂuenza vaccines: global health
diplomacy and the controversies surrounding avian inﬂuenza H5N1 and pan-
demic inﬂuenza H1N1. PLoS Med  2010;7(May (5)):e1000247. http://www.
ncbi.nlm.nih.gov/pubmed/20454566.
